In preclinical studies, NGAL inhibitors (which interfere with NGAL activity in neoplastic and/or tumor stromal cells) include mAbs against NGAL/NGAL-R and small, selective siderophore inhibitors [262]. Here, LCN2 is linked to neoplasm.